KLAC KLA Corporation

Q4 2025 10-Q

Filed: Jan 30, 2026Period ending Dec 31, 2025

Health Care

Optical Instruments & LensesSEC EDGAR

KLA Corporation (KLAC) 10-Q quarterly report for Q4 2025, filed with SEC EDGAR on Jan 30, 2026 for the fiscal period ending Dec 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q4 2025 10-Q

Management Discussion & Analysis

• Working capital $7.28B Dec 2025, up $668.3M from $6.61B June 2025
• Cash, cash equivalents, marketable securities $5.21B plus $1.50B Revolving Credit Facility availability

+3 more insights

Risk Factors

• New risk: 2025 BIS Rules and Affiliates Rule suspend/revised, expanding export controls and compliance complexity in China with suspension extended to Nov 2026
• Updated regulatory risk: OBBBA tax law effective July 2025 modifies GILTI and FDII rules, materially affecting effective tax rate going forward

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$3.3B

▲ +7.2% YoY▲ +2.7% QoQ

Net Income

$1.1B

▲ +39.0% YoY▲ +2.2% QoQ

Net Margin

34.7%

▲ +795bp YoY▼ -18bp QoQ

ROE

21.0%

▼ -204bp YoY

Total Assets

$16.7B

▲ +11.5% YoY

EPS (Diluted)

$8.68

▲ +40.9% YoY▲ +2.5% QoQ

Operating Cash Flow

$1.4B

▲ +61.0% YoY▲ +17.7% QoQ

Source: XBRL data from KLA Corporation Q4 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other KLA Corporation Quarterly Reports

Q3 2025 10-Q

Q1 2025 10-Q

Get deeper insights on KLA Corporation

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.